Phase 1 Clinical Trial of Trametinib and Ponatinib in Patients With NSCLC Harboring KRAS Mutations

por Arbour, Kathryn C., Manchado, Eusebio, Bott, Matthew J., Ahn, Linda, Tobi, Yosef, Ni, Andy Ai, Yu, Helena A., Shannon, Alyssa, Ladanyi, Marc, Perron, Victoria, Ginsberg, Michelle S., Johnson, Amanda, Holodny, Andrei, Kris, Mark G., Rudin, Charles M., Lito, Piro, Rosen, Neal, Lowe, Scott, Riely, Gregory J.
Publicado 2021